Which MASH Drug for Which Patient: A Plain-English Guide for 2026

MASH stands for metabolic dysfunction-associated steatohepatitis. It used to be called NASH. In plain terms: fat builds up in your liver, the fat causes inflammation, the inflammation causes scarring, and over years the scarring can progress to cirrhosis and liver failure. It's tied to obesity, type 2 diabetes, and metabolic syndrome. Roughly 1 in 3 adults with overweight or obesity has some form of fatty liver disease, and a big chunk of them have MASH without knowing it — the disease is mostly silent until it's advanced. The scarring is measured on a scale from F0 (no scarring) to F4 (cirrhosis). Most drug treatment focuses on F2 and F3 — moderate to advanced scarring that hasn't yet become cirrhosis.

As of mid-2026, two drugs are FDA-approved for MASH.

Rezdiffra (resmetirom) was approved in March 2024 — the first drug ever approved specifically for MASH. It's a once-daily pill, not a peptide. It works on a thyroid hormone receptor in the liver (called THR-beta) to help the liver burn off fat. It's approved for adults with noncirrhotic MASH and F2-F3 scarring. The catch: it costs about $47,400 a year ($3,950 a month) cash, has no generic, and getting insurance to cover it usually requires documenting your fibrosis stage, sometimes with a liver biopsy.

Semaglutide (the same drug as Wegovy and Ozempic) got FDA approval for MASH with fibrosis in August 2025, based on the big ESSENCE trial. It's a weekly injection. It works on the GLP-1 system — the same way it produces weight loss and blood sugar control. For MASH it reduces liver fat, inflammation, and scarring, and it has the bonus of treating the obesity and diabetes that usually come with MASH. At EASL 2026 this week, Novo Nordisk showed it works consistently across underrepresented groups, including Japanese patients and women in menopause.

So the practical 2026 choice between approved options comes down to: a liver-targeted pill that does one job well (Rezdiffra), versus a weekly injection that treats the liver plus the obesity and diabetes underneath it (semaglutide).

Here's how doctors are starting to choose between the two approved drugs.

Rezdiffra makes more sense if: your main problem is the liver scarring itself, you don't have much weight to lose, you can't tolerate GLP-1 side effects, or you specifically want a pill over an injection. The liver-fibrosis data is the strongest reason to pick it — it was approved on biopsy-proven scarring improvement.

Semaglutide makes more sense if: you have obesity or type 2 diabetes alongside the MASH (which most MASH patients do), you'd benefit from the weight loss and cardiovascular protection, or your insurance covers it more easily through the obesity or diabetes indication. The big advantage is that it treats the whole metabolic picture — the liver plus the obesity and diabetes driving it.

In practice, some patients end up on both — Rezdiffra for the direct liver-scarring effect plus semaglutide for the weight and metabolic side. There's no head-to-head trial telling us the combination is better than either alone, but the mechanisms don't overlap, so combining them is a reasonable approach that some specialists are already using.

The honest reality: cost and insurance drive a lot of these decisions. Rezdiffra's $47,400 price tag and biopsy-documentation requirement are real barriers. Semaglutide's coverage depends on whether your plan treats it as an obesity drug, a diabetes drug, or a MASH drug — and those have different rules.

The most-watched group of MASH drugs in development pairs GLP-1 with a second hormone called glucagon. Glucagon, despite its reputation for raising blood sugar, does something useful for the liver: it tells the liver to burn fat. Combining it with GLP-1 cancels out the blood-sugar problem and amplifies the fat-burning. These are all weekly injectable peptides.

Survodutide (Boehringer Ingelheim and Zealand Pharma) had its full 48-week Phase 2 results published in the New England Journal of Medicine alongside EASL 2026 this week. The numbers were strong: MASH improved without scarring getting worse in 47% to 62% of patients depending on dose, versus 14% on placebo, and up to 52% saw their fibrosis stage improve. It's now in two big Phase 3 trials — one for F2-F3 MASH, one for cirrhosis. Survodutide also produced 16.6% weight loss in a separate obesity trial.

Pemvidutide (Altimmune) presented its 48-week data at EASL 2026 today. Its abstract was picked as 'Best of EASL 2026.' The standout feature is its effect on cardiovascular risk factors — the 1.8 mg dose cut triglycerides 23.7%, total cholesterol 15.4%, body weight 7.5%, and waist size by more than 5 cm, all with about 1% of patients quitting due to side effects. Pemvidutide's pitch is the lipid and heart-risk benefit on top of the liver effect.

DA-1726 (MetaVia) is earlier — it showed Phase 1 data at EASL with a full readout due late 2026.

All three are 2-4 years from possible approval. Survodutide is furthest along.

A different group of drugs targets a hormone called FGF21. These aren't GLP-1 drugs and don't primarily cause weight loss. Their strength is acting directly on liver scarring, which makes them especially interesting for the harder-to-treat patients with advanced fibrosis or early cirrhosis.

The FGF21 field got expensive fast. Novo Nordisk bought Akero Therapeutics (maker of efruxifermin) for $5.2 billion. Roche bought 89bio (maker of pegozafermin) for around $3.5 billion. That's roughly $9 billion in deals for two drugs that aren't approved yet — a sign of how much the big companies believe FGF21 will matter for the advanced-fibrosis patients.

Efruxifermin (Akero/Novo) had a mixed but encouraging Phase 2b record: it missed its main goal at 36 weeks but at 96 weeks, 29% of patients on the high dose saw fibrosis improve versus placebo. It's now in the Phase 3 SYNCHRONY program covering F2-F3 MASH, real-world patients, and cirrhosis. The cirrhosis trial is the one to watch — that's the population with the fewest options.

Pegozafermin (89bio/Roche) showed fibrosis improvement at 24 weeks in Phase 2 and is in the Phase 3 ENLIGHTEN-Fibrosis trial.

The likely role for FGF21 drugs: the advanced-fibrosis and cirrhosis patients where the GLP-1 drugs and Rezdiffra have less data. If the Phase 3 cirrhosis trials hit, these become the go-to for the sickest patients.

A few more drug types showed up at EASL 2026 this week, each taking a different angle on the liver.

Aligos ALG-055009 is another THR-beta pill, the same target as Rezdiffra. It cut liver fat by up to 46% at 12 weeks in a Phase 2 trial. If it pans out, it could become a lower-cost competitor to Rezdiffra on the same mechanism.

Arrowhead ARO-INHBE is an RNAi drug — it silences a gene that controls fat storage. On its own it cut liver fat 44%, but the eye-catching result was in combination with a low dose of tirzepatide, where it doubled weight loss and tripled fat reduction versus tirzepatide alone. It's dosed roughly twice a year, which is a very different routine than weekly injections.

Sagimet denifanstat blocks an enzyme (FASN) that makes new fat in the liver. It's being tested in combination with Rezdiffra.

Galectin belapectin targets liver scarring through a different protein (galectin-3) and is being tested specifically in cirrhosis.

Inventiva lanifibranor is a pill targeting the PPAR receptor family, in a Phase 3 trial finishing in late 2026.

None of these is approved. They matter because they show MASH is becoming a multi-drug field — different mechanisms for different patients, and combinations layering them together.

A rough framework based on where the evidence stands in 2026.

If you have MASH with F2-F3 scarring and significant obesity or type 2 diabetes: semaglutide is a strong first choice. It treats the liver and the metabolic problems underneath it, and your insurance may cover it through the obesity or diabetes route. If the liver scarring is the dominant concern, adding or switching to Rezdiffra is reasonable.

If you have MASH with F2-F3 scarring but you're not very overweight: Rezdiffra is the more targeted choice. The liver-fibrosis data is what it was approved on, and you won't get as much benefit from a weight-loss-driven drug if you don't have much weight to lose.

If you can't tolerate GLP-1 side effects (nausea, vomiting): Rezdiffra is the alternative, since it's a different mechanism with a different side-effect profile.

If you have early cirrhosis (F4): this is the hardest group, and the approved drugs have the least data here. Talk to a hepatologist about clinical trials — the FGF21 drugs (efruxifermin, pegozafermin) and survodutide all have cirrhosis trials running, and trial enrollment may be the best route to the newest options.

If cost is the barrier: semaglutide through an obesity or diabetes indication is often more accessible than Rezdiffra's $47,400 cash price. Generic semaglutide is coming in some countries (and the US patent cliff is December 2031), which will eventually change the cost math.

If you're early-stage (F0-F1) or just have fatty liver without much scarring: drug treatment usually isn't the answer yet. Weight loss through any route — lifestyle, GLP-1 for the metabolic indication, or bariatric surgery — is the foundation. The approved MASH drugs target moderate-to-advanced scarring, not early disease.

The MASH treatment map will look different by 2028. Here's what to watch.

Survodutide Phase 3 readouts (LIVERAGE for F2-F3, LIVERAGE-Cirrhosis for F4) are the next major data drops. If they confirm the Phase 2 numbers, survodutide becomes a leading GLP-1/glucagon option, possibly approved 2027-2028.

The FGF21 cirrhosis trials (efruxifermin SYNCHRONY Outcomes, pegozafermin programs) are the highest-stakes readouts because cirrhosis is the population with the worst prognosis and fewest options. Positive results would give the sickest patients a real drug.

Retatrutide's MASLD Phase 3 (Eli Lilly's triple agonist) reads out around H1 2027, building on an 86% liver-fat reduction in Phase 2. If positive, retatrutide could file for MASH alongside its obesity approval.

Combination therapy is the emerging theme. The Arrowhead-plus-tirzepatide data this week, the Sagimet-plus-Rezdiffra trials, and the general logic of layering a liver-targeted drug with a weight-loss drug all point toward combinations becoming standard for harder cases.

The practical upshot: MASH is going from zero drugs in 2023 to a crowded, multi-mechanism field by 2028. For patients, that means more options matched to your specific situation — your scarring stage, your weight, your diabetes status, your tolerance for injections, and your insurance. For now, the two approved drugs cover the largest group of patients (F2-F3 with metabolic disease), and the conversation with your doctor is mostly about which of those two — or both — fits you best.

MASH treatment in 2026 is early but real. Two years ago a MASH diagnosis came with diet-and-exercise advice and nothing else. Now there are two approved drugs and a deep pipeline, with fresh data landing at EASL 2026 this week across nearly every mechanism.

For most patients, the decision is simpler than the crowded pipeline suggests. If you have MASH with moderate-to-advanced scarring plus the usual obesity or diabetes, semaglutide treats the whole picture and is often the most accessible. If the liver scarring is the main event and you want a targeted pill, Rezdiffra is the approved option built for exactly that. Everything else — survodutide, pemvidutide, the FGF21 drugs, the combinations — is promising but still 2-4 years from your pharmacy.

The single most important thing isn't which drug. It's getting diagnosed and staged in the first place. MASH is silent, most cases are undiagnosed, and the drugs work best at the F2-F3 stage before cirrhosis sets in. If you have obesity, type 2 diabetes, or metabolic syndrome, ask your doctor about a FibroScan or other non-invasive liver test. The treatment options are finally here. The harder problem is that most people who could benefit don't yet know they have the disease.